@sawroast95
Active 1 year, 3 months ago
Eculizumab is approved for the treatment of atypical hemolytic uremic syndrome (aHUS). Its use off-label is frequently reported. The aim of this study was to describe the broader use and outcomes of a cohort of pediatric patients exposed to eculizumab.
A retrospective, cohort analysis was performed on the clinical and biomarker […] View